Target Details
| UniProt AC | O60674 |
|---|---|
| Gene Symbol | JAK2 |
| Protein Name | Tyrosine-protein kinase JAK2 |
| Organism | Homo sapiens |
| Entry Name | |
| Organism Category | Human |
| Pfam Domains | PF18379 (FERM_F1) PF18377 (FERM_F2) PF17887 (Jak1_Phl) PF07714 (PK_Tyr_Ser-Thr) PF21990 (SH2_1) |
Summary
- Multi-target molecules 10,545
- Clinical molecules 78
- Avg pChEMBL 7.81
KEGG Pathways (26)
- AGE-RAGE signaling pathway in diabetic complications
- Adipocytokine signaling pathway
- Chemical carcinogenesis - receptor activation
- Chemokine signaling pathway
- Cholinergic synapse
- EGFR tyrosine kinase inhibitor resistance
- Efferocytosis
- Growth hormone synthesis, secretion and action
- Hepatitis B
- Herpes simplex virus 1 infection
- Hormone signaling
- Influenza A
- JAK-STAT signaling pathway
- Kaposi sarcoma-associated herpesvirus infection
- Leishmaniasis
- Lipid and atherosclerosis
- Necroptosis
- PD-L1 expression and PD-1 checkpoint pathway in cancer
- PI3K-Akt signaling pathway
- Pathways in cancer
- Prolactin signaling pathway
- Signaling pathways regulating pluripotency of stem cells
- Th1 and Th2 cell differentiation
- Th17 cell differentiation
- Toxoplasmosis
- Tuberculosis
Associated Diseases (9)
Active Molecules (10,545)
| InChIKey | pChEMBL | Type | Targets | Clinical | |
|---|---|---|---|---|---|
BVBZCFHWZWWSIU
|
10.3 | IC50 | 2 | — | |
CAGMYACDPWIQDW
|
10.3 | IC50 | 3 | — | |
CDKWFFPPBGSFBX
|
10.3 | IC50 | 2 | — | |
DKFDJOXMHHYUSX
|
10.3 | IC50 | 2 | — | |
DPAJKHCGADQTTF
|
10.3 | IC50 | 2 | — | |
FIEPDBBGKDUSNR
|
10.3 | IC50 | 2 | — | |
FWXJTNOOTLFTHZ
|
10.3 | IC50 | 2 | — | |
GFJZCOSLDIEWGX
|
10.3 | IC50 | 2 | — | |
GFMSUDIXMJGWQT
|
10.3 | IC50 | 2 | — | |
GGYZGDHKIMHUOW
|
10.3 | IC50 | 2 | — | |
GLRHYIMEWMAJLW
|
10.3 | IC50 | 2 | — | |
HTTFBRAIXNPVEK
|
10.3 | IC50 | 3 | — | |
INNQJNLPVHXGCK
|
10.3 | IC50 | 2 | — | |
JKPQUPJWDOHLEB
|
10.3 | IC50 | 2 | — | |
JKPVBGCJUHOUKU
|
10.3 | IC50 | 2 | — | |
KIDYVTPMDQFDCS
|
10.3 | IC50 | 2 | — | |
KTANGVPPGNDMTF
|
10.3 | IC50 | 3 | — | |
KZTYLBQIWZBZGN
|
10.3 | IC50 | 2 | — | |
LLMKWUGEQJAPRT
|
10.3 | IC50 | 2 | — | |
LOKUADMVMXXXHK
|
10.3 | IC50 | 2 | — | |
MDWNAZJBZGAPCL
|
10.3 | IC50 | 2 | — | |
MMMGUPVPASWGCI
|
10.3 | IC50 | 2 | — | |
MQMOVCVOBXTCLF
|
10.3 | IC50 | 2 | — | |
MQSAXLUCUWDZMY
|
10.3 | IC50 | 2 | — | |
MQVUZFWTNGYJLU
|
10.3 | IC50 | 2 | — | |
MWWBXFIQJUTQKP
|
10.3 | IC50 | 2 | — | |
NKZDARSZVOPRKB
|
10.3 | IC50 | 3 | — | |
OHQOIXITGAQUAT
|
10.3 | IC50 | 3 | — | |
ONJYZFNDMZBOIV
|
10.3 | IC50 | 2 | — | |
PUNOHMZQRDFAEB
|
10.3 | IC50 | 2 | — | |
QGECRLVOKBDJNV
|
10.3 | IC50 | 2 | — | |
QXVLADQSKJNARQ
|
10.3 | IC50 | 2 | — | |
RJDFEVIMBGLEBT
|
10.3 | IC50 | 3 | — | |
RMSRKKFWYZMWLY
|
10.3 | IC50 | 2 | — | |
RSPUYRPBUQKEPS
|
10.3 | IC50 | 2 | — | |
SIZXITCJPWVYEC
|
10.3 | IC50 | 3 | — | |
SSQRGQRRPUZAFS
|
10.3 | IC50 | 2 | — | |
SXUQCPJWCLBWJE
|
10.3 | IC50 | 2 | — | |
SYRVFXRDMPFBNQ
|
10.3 | IC50 | 2 | — | |
UHBCBUQTTGJFLB
|
10.3 | IC50 | 3 | — | |
VYSZNCGWMHJUQE
|
10.3 | IC50 | 2 | — | |
WFVUXNBUCCSRRY
|
10.3 | IC50 | 2 | — | |
WGCLQYPBHLZIGD
|
10.3 | IC50 | 2 | — | |
WOGFXVZMFBBRSN
|
10.3 | IC50 | 2 | — | |
WRKNUXRARNRWJC
|
10.3 | IC50 | 2 | — | |
WUKNKNZOJSDCHK
|
10.3 | IC50 | 2 | — | |
XEKZNZFRNCNSEK
|
10.3 | IC50 | 2 | — | |
XYZMQGQDCDCBRQ
|
10.3 | IC50 | 2 | — | |
XZSUEZDYSFPVPA
|
10.3 | IC50 | 2 | — | |
YKMHHGSJEWTLFF
|
10.3 | IC50 | 2 | — |